Drug intelligence / Profile preview

RBD2080

Development stage: Phase 1
Lead developer: Suzhou Ribo Life Science
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

RBD2080 is a GalNAc-conjugated small interfering RNA (siRNA) therapeutic developed by Suzhou Ribo Life Science. It is designed using the company's proprietary RIBO-GalSTAR liver-targeting technology platform to specifically target and inhibit the expression of complement component 3 (C3) in hepatocytes. By silencing C3 mRNA, RBD2080 reduces the levels of C3 protein at its source and in circulation, thereby preventing the overactivation of the complement system. It is being developed for the treatment of complement-mediated diseases, including renal and autoimmune diseases.

Targets

Beyond the preview

Go deeper on RBD2080.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBD2080.